178 related articles for article (PubMed ID: 30352910)
1. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.
Adam L; San Lucas FA; Fowler R; Yu Y; Wu W; Liu Y; Wang H; Menter D; Tetzlaff MT; Ensor J; Manyam G; Arold ST; Huff C; Kopetz S; Scheet P; Overman MJ
Clin Cancer Res; 2019 Jan; 25(2):641-651. PubMed ID: 30352910
[TBL] [Abstract][Full Text] [Related]
2. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
Laforest A; Aparicio T; Zaanan A; Silva FP; Didelot A; Desbeaux A; Le Corre D; Benhaim L; Pallier K; Aust D; Pistorius S; Blons H; Svrcek M; Laurent-Puig P
Eur J Cancer; 2014 Jul; 50(10):1740-1746. PubMed ID: 24797764
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling of Small-Bowel Adenocarcinoma.
Schrock AB; Devoe CE; McWilliams R; Sun J; Aparicio T; Stephens PJ; Ross JS; Wilson R; Miller VA; Ali SM; Overman MJ
JAMA Oncol; 2017 Nov; 3(11):1546-1553. PubMed ID: 28617917
[TBL] [Abstract][Full Text] [Related]
4. Exome-wide somatic mutation characterization of small bowel adenocarcinoma.
Hänninen UA; Katainen R; Tanskanen T; Plaketti RM; Laine R; Hamberg J; Ristimäki A; Pukkala E; Taipale M; Mecklin JP; Forsström LM; Pitkänen E; Palin K; Välimäki N; Mäkinen N; Aaltonen LA
PLoS Genet; 2018 Mar; 14(3):e1007200. PubMed ID: 29522538
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma.
Pan H; Cheng H; Wang H; Ge W; Yuan M; Jiang S; Wan X; Dong Y; Liu Z; Zhao R; Fang Y; Lou F; Cao S; Han W
Cancer Sci; 2021 Nov; 112(11):4758-4771. PubMed ID: 34449929
[TBL] [Abstract][Full Text] [Related]
6. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
7. Unbiased Detection of Driver Mutations in Extramammary Paget Disease.
Ishida Y; Kakiuchi N; Yoshida K; Inoue Y; Irie H; Kataoka TR; Hirata M; Funakoshi T; Matsushita S; Hata H; Uchi H; Yamamoto Y; Fujisawa Y; Fujimura T; Saiki R; Takeuchi K; Shiraishi Y; Chiba K; Tanaka H; Otsuka A; Miyano S; Kabashima K; Ogawa S
Clin Cancer Res; 2021 Mar; 27(6):1756-1765. PubMed ID: 33323405
[TBL] [Abstract][Full Text] [Related]
8. Genomic
Li M; Liu F; Zhang F; Zhou W; Jiang X; Yang Y; Qu K; Wang Y; Ma Q; Wang T; Bai L; Wang Z; Song X; Zhu Y; Yuan R; Gao Y; Liu Y; Jin Y; Li H; Xiang S; Ye Y; Zhang Y; Jiang L; Hu Y; Hao Y; Lu W; Chen S; Gu J; Zhou J; Gong W; Zhang Y; Wang X; Liu X; Liu C; Liu H; Liu Y; Liu Y
Gut; 2019 Jun; 68(6):1024-1033. PubMed ID: 29954840
[TBL] [Abstract][Full Text] [Related]
9. Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
Aparicio T; Svrcek M; Henriques J; Afchain P; Lièvre A; Tougeron D; Gagniere J; Terrebonne E; Piessen G; Legoux JL; Lecaille C; Pocard M; Gornet JM; Zaanan A; Lavau-Denes S; Lecomte T; Deutsch D; Vernerey D; Puig PL
Int J Cancer; 2021 Apr; 148(7):1731-1742. PubMed ID: 33186471
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma.
Suzuki H; Hirata Y; Suzuki N; Ihara S; Sakitani K; Kobayashi Y; Kinoshita H; Hayakawa Y; Yamada A; Watabe H; Tateishi K; Ikenoue T; Yamaji Y; Koike K
Am J Pathol; 2015 Feb; 185(2):550-62. PubMed ID: 25478808
[TBL] [Abstract][Full Text] [Related]
12. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/β-catenin signaling pathway mutations.
Yuan W; Zhang Z; Dai B; Wei Q; Liu J; Liu Y; Liu Y; He L; Zhou D
Cancer; 2016 Jun; 122(11):1689-96. PubMed ID: 26998897
[TBL] [Abstract][Full Text] [Related]
14. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer.
Iyer P; Shrikhande SV; Ranjan M; Joshi A; Gardi N; Prasad R; Dharavath B; Thorat R; Salunkhe S; Sahoo B; Chandrani P; Kore H; Mohanty B; Chaudhari V; Choughule A; Kawle D; Chaudhari P; Ingle A; Banavali S; Gera P; Ramadwar MR; Prabhash K; Barreto SG; Dutt S; Dutt A
Int J Cancer; 2019 Apr; 144(8):2008-2019. PubMed ID: 30304546
[TBL] [Abstract][Full Text] [Related]
15. Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma.
Latham A; Shia J; Patel Z; Reidy-Lagunes DL; Segal NH; Yaeger R; Ganesh K; Connell L; Kemeny NE; Kelsen DP; Hechtman JF; Nash GM; Paty PB; Zehir A; Tkachuk KA; Sheikh R; Markowitz AJ; Mandelker D; Offit K; Berger MF; Cercek A; Garcia-Aguilar J; Saltz LB; Weiser MR; Stadler ZK
Clin Cancer Res; 2021 Mar; 27(5):1429-1437. PubMed ID: 33199489
[TBL] [Abstract][Full Text] [Related]
16. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Quaas A; Heydt C; Waldschmidt D; Alakus H; Zander T; Goeser T; Kasper P; Bruns C; Brunn A; Roth W; Hartmann N; Bunck A; Schmidt M; Buettner R; Merkelbach-Bruse S
BMC Gastroenterol; 2019 Feb; 19(1):21. PubMed ID: 30717682
[TBL] [Abstract][Full Text] [Related]
17. Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.
Birkeland AC; Yanik M; Tillman BN; Scott MV; Foltin SK; Mann JE; Michmerhuizen NL; Ludwig ML; Sandelski MM; Komarck CM; Carey TE; Prince ME; Bradford CR; McHugh JB; Spector ME; Brenner JC
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):559-67. PubMed ID: 27077364
[TBL] [Abstract][Full Text] [Related]
18. Rates of
Gottesdiener LS; O'Connor S; Busam KJ; Won H; Solit DB; Hyman DM; Shoushtari AN
Clin Cancer Res; 2018 Dec; 24(23):5815-5819. PubMed ID: 30093446
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
20. Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations.
Selenica P; Alemar B; Matrai C; Talia KL; Veras E; Hussein Y; Oliva E; Beets-Tan RGH; Mikami Y; McCluggage WG; Kiyokawa T; Weigelt B; Park KJ; Murali R
Mod Pathol; 2021 Jun; 34(6):1213-1225. PubMed ID: 33318584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
